Cargando…

Switch in FOXA1 Status Associates with Endometrial Cancer Progression

BACKGROUND: The transcription factor Forkhead box A1 (FOXA1) is suggested to be important in hormone dependent cancers, although with little data for endometrial cancer. We investigated expression levels of FOXA1 in primary and metastatic endometrial cancer in relation to clinical phenotype, and tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tangen, Ingvild Løberg, Krakstad, Camilla, Halle, Mari K., Werner, Henrica M. J., Øyan, Anne M., Kusonmano, Kanthida, Petersen, Kjell, Kalland, Karl Henning, Akslen, Lars A., Trovik, Jone, Hurtado, Antoni, Salvesen, Helga B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029819/ https://www.ncbi.nlm.nih.gov/pubmed/24849812 http://dx.doi.org/10.1371/journal.pone.0098069

Ejemplares similares

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer
por: Kusonmano, Kanthida, et al.
Publicado: (2018)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Androgen receptor as potential therapeutic target in metastatic endometrial cancer
por: Tangen, Ingvild Løberg, et al.
Publicado: (2016)

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene
por: Hoivik, Erling A., et al.
Publicado: (2014)

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
por: Krakstad, Camilla, et al.
Publicado: (2012)

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
por: Krakstad, Camilla, et al.
Publicado: (2015)

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival
por: Mauland, Karen Klepsland, et al.
Publicado: (2016)

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer
por: Mjos, Siv, et al.
Publicado: (2017)

Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
por: Werner, Henrica M. J., et al.
Publicado: (2014)

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients
por: Berg, Anna, et al.
Publicado: (2014)

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer
por: Stefansson, Ingunn M., et al.
Publicado: (2015)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

Lipocalin 2 expression is associated with aggressive features of endometrial cancer
por: Mannelqvist, Monica, et al.
Publicado: (2012)

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer
por: Engerud, Hilde, et al.
Publicado: (2019)

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses
por: Bredholt, Geir, et al.
Publicado: (2015)

High visceral fat percentage is associated with poor outcome in endometrial cancer
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers
por: Berg, Anna, et al.
Publicado: (2017)

Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer
por: Berg, Anna, et al.
Publicado: (2016)

Blood Metabolites Associate with Prognosis in Endometrial Cancer
por: Strand, Elin, et al.
Publicado: (2019)

Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease
por: Lien, Hilde E., et al.
Publicado: (2023)

Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients
por: Tangen, Ingvild L, et al.
Publicado: (2017)

Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595]
por: Lien, Hilde E., et al.
Publicado: (2023)

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation
por: Karlsson, Thomas, et al.
Publicado: (2016)

Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers
por: Raeder, Maria B., et al.
Publicado: (2013)

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
por: Krakstad, C, et al.
Publicado: (2012)

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis
por: Gibson, William J., et al.
Publicado: (2016)

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer
por: Mauland, K K, et al.
Publicado: (2011)

Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma
por: Berg, Hege F., et al.
Publicado: (2020)

Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer
por: Wagner-Larsen, Kari S., et al.
Publicado: (2022)

Whole‐Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

Preoperative Tumor Size at MRI Predicts Deep Myometrial Invasion, Lymph Node Metastases, and Patient Outcome in Endometrial Carcinomas
por: Ytre-Hauge, Sigmund, et al.
Publicado: (2015)

Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
por: Lura, Njål, et al.
Publicado: (2022)

Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma
por: Engelsen, I B, et al.
Publicado: (2008)

Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value
por: Berg, Hege F., et al.
Publicado: (2022)

MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer
por: Dybvik, Julie Andrea, et al.
Publicado: (2022)

Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study
por: Njølstad, Tormund S., et al.
Publicado: (2017)

Preoperative pelvic MRI and 2-[(18)F]FDG PET/CT for lymph node staging and prognostication in endometrial cancer—time to revisit current imaging guidelines?
por: Fasmer, Kristine E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p74ur216peen91tl80av09vg54